Randomised placebo-controlled trial of intravenous methylprednisolone in relapsed multiple sclerosis patients without the need for ranitidine cover
Not Applicable
Completed
- Conditions
- ervous System Diseases: Multiple sclerosis (MS)Nervous System DiseasesMultiple sclerosis
- Registration Number
- ISRCTN46231139
- Lead Sponsor
- Department of Health (UK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 60
Inclusion Criteria
Sixty matched patients from those admitted for intravenous methylprednisolone treatment for their relapsed multiple sclerosis.
Exclusion Criteria
Not provided at time of registration
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Between group differences in the absolute number of those who develop gastro-intestinal symptoms.
- Secondary Outcome Measures
Name Time Method The number of those who develop gastro-intestinal symptoms who on clinical grounds require further investigation of their gastric mucosa for a possible ulcer or erosions in the 3, 6 and 12 months follow up durations.